H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM) today and set a price target of $65.00. The company’s shares closed last Tuesday at $8.16.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 37.7% and a 68.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $38.75, which is a 346.9% upside from current levels. In a report released today, JonesTrading also reiterated a Buy rating on the stock with a $40.00 price target.
See today’s analyst top recommended stocks >>
Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.54 million. In comparison, last year the company had a GAAP net loss of $6.6 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
